Cargando…

Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1

BACKGROUND: Gliomas are the most common primary brain tumors. High-Grade Gliomas have a median survival (MS) of 18 months, while Low-Grade Gliomas (LGGs) have an MS of approximately 7.3 years. Seventy-six percent of patients with LGG express mutated isocitrate dehydrogenase (mIDH) enzyme. Survival o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alghamri, Mahmoud S, Thalla, Rohit, Avvari, Ruthvik P, Dabaja, Ali, Taher, Ayman, Zhao, Lili, Ulintz, Peter J, Castro, Maria G, Lowenstein, Pedro R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212865/ https://www.ncbi.nlm.nih.gov/pubmed/32642696 http://dx.doi.org/10.1093/noajnl/vdaa042

Ejemplares similares

IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas
por: Zhang, Lei, et al.
Publicado: (2018)

Glycolytic expression in lower-grade glioma reveals an epigenetic association between IDH mutation status and PDL1/2 expression
por: Givechian, Kevin B, et al.
Publicado: (2020)

G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy
por: Alghamri, Mahmoud S., et al.
Publicado: (2021)

Pharmacoresistant seizures and IDH mutation in low-grade gliomas
por: Correia, Carlos Eduardo, et al.
Publicado: (2021)

TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors
por: Cantero, Diana, et al.
Publicado: (2020)

MRI-based classification of IDH mutation and 1p/19q codeletion status of gliomas using a 2.5D hybrid multi-task convolutional neural network
por: Chakrabarty, Satrajit, et al.
Publicado: (2023)

Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma
por: Jones, Lindsey E, et al.
Publicado: (2020)

Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures
por: Verheul, Cassandra, et al.
Publicado: (2021)

Multicellular “hotspots” harbor high-grade potential in lower-grade gliomas
por: Kirby, Alastair J, et al.
Publicado: (2021)

Monitoring response to a clinically relevant IDH inhibitor in glioma—Hyperpolarized (13)C magnetic resonance spectroscopy approaches
por: Hong, Donghyun, et al.
Publicado: (2023)

Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort
por: van Garderen, Karin A, et al.
Publicado: (2023)

Establishment of patient-derived organoid models of lower-grade glioma
por: Abdullah, Kalil G, et al.
Publicado: (2021)

High-throughput microRNA profiling of pediatric high-grade gliomas
por: Miele, Evelina, et al.
Publicado: (2014)

An affinity for brainstem microglia in pediatric high-grade gliomas of brainstem origin
por: Zats, Liat Peretz, et al.
Publicado: (2022)

MR-guided focused ultrasound increases antibody delivery to nonenhancing high-grade glioma
por: Brighi, Caterina, et al.
Publicado: (2020)

Parents’ experiences of postmortem tumor donation for high-grade gliomas: benefits and suggested improvements
por: Robertson, Eden G, et al.
Publicado: (2021)

Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning
por: van der Voort, Sebastian R, et al.
Publicado: (2022)

An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect
por: Rahal, Farah, et al.
Publicado: (2022)

Structural gray matter alterations in glioblastoma and high-grade glioma—A potential biomarker of survival
por: Lamichhane, Bidhan, et al.
Publicado: (2023)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

Outcomes after combined use of intraoperative MRI and 5-aminolevulinic acid in high-grade glioma surgery
por: Schatlo, Bawarjan, et al.
Publicado: (2015)

The natural compound obtusaquinone targets pediatric high-grade gliomas through ROS-mediated ER stress
por: Teng, Jian, et al.
Publicado: (2020)

Transitioning to molecular diagnostics in pediatric high-grade glioma: experiences with the 2016 WHO classification of CNS tumors
por: Baugh, Joshua N, et al.
Publicado: (2021)

Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement
por: Chang, Ken, et al.
Publicado: (2019)

Deep proteome investigation of high-grade gliomas reveals heterogeneity driving differential metabolism of 5-aminolevulinic acid
por: Ghantasala, Saicharan, et al.
Publicado: (2023)

Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas
por: Cano-Galiano, Andrés, et al.
Publicado: (2021)

Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks
por: Li, Kay Ka-Wai, et al.
Publicado: (2019)

Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay
por: Shuford, Stephen, et al.
Publicado: (2021)

Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients
por: Izquierdo, Elisa, et al.
Publicado: (2021)

Immune deconvolution and temporal mapping identifies stromal targets and developmental intervals for abrogating murine low-grade optic glioma formation
por: de Andrade Costa, Amanda, et al.
Publicado: (2021)

Pediatric high-grade gliomas and the WHO CNS Tumor Classification—Perspectives of pediatric neuro-oncologists and neuropathologists in light of recent updates
por: Gielen, Gerrit H, et al.
Publicado: (2022)

Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Early-onset grade 2-3 diffuse gliomas and schwannomas increase the risk of central nervous system tumors among the patients’ relatives
por: Alanen, Eljas, et al.
Publicado: (2023)

Seizures in patients with IDH-mutated lower grade gliomas
por: Carstam, Louise, et al.
Publicado: (2022)

Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-β signaling in recurrent tumors
por: Kashani, Elham, et al.
Publicado: (2022)

IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas
por: Duan, Wen-chao, et al.
Publicado: (2018)

Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma
por: Messinger, Dana, et al.
Publicado: (2022)

Driver mutations in USP8 wild-type Cushing’s disease
por: Sbiera, Silviu, et al.
Publicado: (2019)

Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status
por: Unger, Kristian, et al.
Publicado: (2020)

The spectrum of mitochondrial DNA (mtDNA) mutations in pediatric CNS tumors
por: Kaneva, Kristiyana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_58dd7it9rb219ub917fr39usb0